CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.


Updates from The Motley Fool

Latest updates on CRISPR Therapeutics from Fool.com.  The Fool has written over 100 articles on CRISPR Therapeutics.
Is CRISPR Therapeutics AG a Buy?

On one hand, there's the promise of a groundbreaking technology. On the other hand, huge risk. Wh...



Stock Performance

View Interactive CRSP Charts
Sponsored by

Key Data Points

Primary metrics and data points about CRISPR Therapeutics.
Current Price: $35.71
Prev Close: $35.30
Open: $35.93
Bid: $35.50
Ask: $36.30
Day's Range: $35.15 - $36.42
52wk Range: $17.40 - $73.90
Volume: 695,618
Avg Vol 782,160
Market Cap: $2B
P/E (ttm): -14.12
EPS (ttm): -$2.50
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about CRISPR Therapeutics.
CAPS Rating 4 out of 5
 
110 Outperform
5 Underperform
CAPS All Stars
 
32 Outperform
1 Underperform

How do you think CRISPR Therapeutics will perform against the market?



You pick for CRISPR Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for CRISPR Therapeutics.

CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.

  • Exchange: NASDAQ